Targeted metabolomic analysis of plasma fatty acids in acute myocardial infarction in young adults

Guo, Manyun; Fan, Xiaojuan; Tuerhongjiang, Gulinigaer; Wang, Chen; Wu, Haoyu; Lou, Bowen; Wu, Yue; Yuan, Zuyi; She, Jianqing

doi:10.1016/j.numecd.2021.06.024

Cited by 18 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, trimethylamine N-oxide (TMAO), a gut microbial metabolite, has been demonstrated to be associated with extremely late stent thrombosis, coronary plaque rupture, platelet hyperreactivity, and future CAD risk (26)(27)(28)(29). Short-chain fatty acids (SCFAs), another kind of significant GM-derived metabolites, have also been proved to play important roles in the pathological process of hypertensive cardiovascular damage, AF, and AMI (30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis

Yang

Chen

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectiveThis study was designed to explore the predictive value of plasma phenylalanine (Phe) and gut microbiota-derived metabolite phenylacetylglutamine (PAGln) in coronary in-stent restenosis (ISR).MethodsPatients with coronary ISR, in-stent hyperplasia (ISH), and in-stent patency (ISP) were retrospectively enrolled in this study. Multivariable logistic regression analyses were used to identify independent risk factors of ISR. The predictive value of plasma Phe and PAGln levels was evaluated by receiver operating characteristic (ROC) curve analysis. The areas under the ROC curve (AUCs) were compared using the Z-test. The correlation between PAGln and clinical characteristics were examined using Spearman's correlation analysis.ResultsSeventy-two patients (mean age, 64.74 ± 9.47 years) were divided into three groups according to coronary stent patency: ISR (n = 28), ISH (n = 11), and ISP (n = 33) groups. The plasma levels of Phe and PAGln were significantly higher in the ISR group than in the ISP group. PAGln was positively associated with the erythrocyte sedimentation rate, homocysteine, SYNTAX score, triglyceride to high-density lipoprotein ratio, Phe, and microbiota-related intermediate metabolite phenylacetic acid (PA). In the ISR group, with the aggravation of restenosis, PAGln levels were also elevated. In multivariate regression analyses, Phe, PAGln and SYNTAX score were independent predictors of coronary ISR (all P < 0.05). In the ROC curve analyses, both Phe [AUC = 0.732; 95% confidence interval (CI), 0.606–0.858; P = 0.002] and PAGln (AUC = 0.861; 95% CI, 0.766–0.957; P < 0.001) had good discrimination performance in predicting coronary ISR, and the predictive power of PAGln was significantly better (P = 0.031).ConclusionPlasma Phe and PAGln are valuable indices for predicting coronary ISR, and gut microbes may be a promising intervention target to prevent ISR progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis

Yang

Chen

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…It is well known that lipid metabolism in the heart and throughout the body is closely related to the occurrence and development of coronary heart disease. 12 , 13 , 14 , 15 Studies have shown that the heart is a highly energy‐intensive organ that needs an adequate supply of blood oxygen to maintain normal function. In general, 60%–90% of the energy required for myocardial activity comes from free fatty acids, and the other 10%–40% of the energy is provided by the metabolism of carbohydrates (glucose, lactic acid, and ketone bodies).…”

Section: Discussionmentioning

confidence: 99%

“…It is well known that lipid metabolism in the heart and throughout the body is closely related to the occurrence and development of coronary heart disease 12–15 . Studies have shown that the heart is a highly energy‐intensive organ that needs an adequate supply of blood oxygen to maintain normal function.…”

Section: Discussionmentioning

confidence: 99%

Metabolomic and transcriptomic studies of improvements in myocardial infarction due to Pycr1 deletion

Xue

Pan

Kong

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Myocardial infarction (MI) remains a major challenge to cardiovascular health worldwide, with poor healing leaving a direct impact on patients' quality of life and survival.Metabolic abnormalities after MI are receiving increasing attention. Our previous studies showed that enhancing proline catabolism ameliorates hypoxic damage to myocardial cells; therefore, we sought to determine whether reducing the synthesis of endogenous proline also affects MI. We analysed GEO datasets associated with MI and western blot of mouse heart tissue in an MI model to demonstrate pyrroline-5carboxylate reductase 1 (Pycr1) expression level after MI. We constructed Pycr1 KO mice by CRISPR/Cas9 technology to explore the effect of Pycr1 gene KO after MI using transcriptomic and metabolomic techniques. In this study, we found reduced mRNA and protein expression levels of Pycr1 in the hearts of mice after MI. We observed that Pycr1 gene KO has a protective effect against MI, reducing the area of MI and improving heart function. Using transcriptomics approaches, we found 215 upregulated genes and 247 downregulated genes after KO of the Pycr1 gene, indicating that unsaturated fatty acid metabolism was affected at the transcriptional level.Metabolomics results revealed elevated content for 141 metabolites and decreased content for 90 metabolites, among which the levels of fatty acids, glycerol phospholipids, bile acids, and other metabolites increased significantly. The changes in these metabolites may be related to the protective effect of Pycr1 KO on the heart after MI. Pycr1 gene KO has a protective effect against MI and our research will lay a solid foundation for the development of future Pycr1-related drug targets.

show abstract

“…A recent study showed that maternal 3, 3-dimethyl-1-butano could increase the plasma acetic acid, reduce the expression of GPR43 and GPR109A, and thus help to favor vasodilatation and lower BP (Hsu et al 2021 ). SCFA in patients with acute myocardial infarction was significantly lower than that in healthy controls, indicating that it may be a marker for the diagnosis of transient myocardial infarction (Guo et al 2021 ). Propionic acid has parasympathetic excitatory effect.…”

Section: Changes In Microbial Metabolitesmentioning

confidence: 99%

Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives

Yuan,

Li,

Chen

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Cardiometabolic disease (CMD) encompasses a range of diseases such as hypertension, atherosclerosis, heart failure, obesity, and type 2 diabetes. Recent findings about CMD’s interaction with gut microbiota have broadened our understanding of how diet and nutrition drive microbes to influence CMD. However, the translation of basic research into the clinic has not been smooth, and dietary nutrition and probiotic supplementation have yet to show significant evidence of the therapeutic benefits of CMD. In addition, the published reviews do not suggest the core microbiota or metabolite classes that influence CMD, and systematically elucidate the causal relationship between host disease phenotypes-microbiome. The aim of this review is to highlight the complex interaction of the gut microbiota and their metabolites with CMD progression and to further centralize and conceptualize the mechanisms of action between microbial and host disease phenotypes. We also discuss the potential of targeting modulations of gut microbes and metabolites as new targets for prevention and treatment of CMD, including the use of emerging technologies such as fecal microbiota transplantation and nanomedicine. Key points • To highlight the complex interaction of the gut microbiota and their metabolites with CMD progression and to further centralize and conceptualize the mechanisms of action between microbial and host disease phenotypes. • We also discuss the potential of targeting modulations of gut microbes and metabolites as new targets for prevention and treatment of CMD, including the use of emerging technologies such as FMT and nanomedicine. • Our study provides insight into identification-specific microbiomes and metabolites involved in CMD, and microbial-host changes and physiological factors as disease phenotypes develop, which will help to map the microbiome individually and capture pathogenic mechanisms as a whole. Graphical Abstract

show abstract

Targeted metabolomic analysis of plasma fatty acids in acute myocardial infarction in young adults

Cited by 18 publications

References 38 publications

Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis

Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis

Metabolomic and transcriptomic studies of improvements in myocardial infarction due to Pycr1 deletion

Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives

Contact Info

Product

Resources

About